| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA3221246
Max Phase: Preclinical
Molecular Formula: C20H21NO2S
Molecular Weight: 339.46
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCOC(=O)C1=C(C)NC(c2ccc(C)cc2)=CC1c1cccs1
Standard InChI: InChI=1S/C20H21NO2S/c1-4-23-20(22)19-14(3)21-17(15-9-7-13(2)8-10-15)12-16(19)18-6-5-11-24-18/h5-12,16,21H,4H2,1-3H3
Standard InChI Key: RNCVNIOVMAWDNH-UHFFFAOYSA-N
Associated Targets(Human)
SH-SY5Y 11521 Activities
Voltage-gated L-type calcium channel alpha-1D subunit 39 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Voltage-gated L-type calcium channel alpha-1C subunit 1321 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 339.46 | Molecular Weight (Monoisotopic): 339.1293 | AlogP: 4.62 | #Rotatable Bonds: 4 |
| Polar Surface Area: 38.33 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.21 | CX LogD: 4.21 |
| Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.83 | Np Likeness Score: -0.97 |
References
| 1. Tenti G, Egea J, Villarroya M, Leon R, Fernandez JC, Padin JF, Sridharan V, Ramos MT, Menendez JC. (2013) Identification of 4,6-diaryl-1,4-dihydropyridines as a new class of neuroprotective agents, 4 (3): [10.1039/C3MD20345J] |
| 2. Tenti G, Parada E, León R, Egea J, Martínez-Revelles S, Briones AM, Sridharan V, López MG, Ramos MT, Menéndez JC.. (2014) New 5-unsubstituted dihydropyridines with improved CaV1.3 selectivity as potential neuroprotective agents against ischemic injury., 57 (10): [PMID:24754640] [10.1021/jm500263v] |
Source
Source(1):